secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001326190-25-000011
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune posts Q4 net loss $23.2M; CMO to retire; pemvidutide MASH data on track
--------------------------------------------------------------------------------

- Net loss Q4 2024 $23.2M ($0.33/share) vs $31.6M in Q4 2023 (incl $12.4M impairment); FY2024 net loss $95.1M ($1.34/share).
- Cash, cash equivalents and short-term investments $131.9M at Dec 31, 2024.
- CMO Dr. Scott Harris will retire effective Feb 28, 2026; company to search for successor.
- Top-line data from Phase 2b IMPACT MASH trial expected Q2 2025; IND cleared for two additional indications with Phase 2 trials mid-2025.
- Board adds Teri Lawver (ex-Dexcom, J&J) and Jerry Durso (ex-Intercept CEO, Sanofi).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000132619025000011/0001326190-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000132619025000011/alt-20250224x8k.htm
  HTML page:      https://secwatch.observer/filing/0001326190-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer